Delving into the Latest Updates on CAP nanoparticles(BioSante Pharmaceuticals) with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

BioVant

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

AnthraxInfluenza, HumanMalaria

Originator Organization

Biosante Pharmaceuticals

Active Organization-

Inactive Organization

Biosante Pharmaceuticals

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

ETHNOPHARMACOLOGICAL RELEVANCECough variant asthma (CVA), a prevalent chronic inflammatory disease, is the most common cause of chronic cough. Over the years, the aqueous extract of Quzhou Aurantii Fructus (QAFA) has been widely used to treat respiratory diseases, particularly cough.AIM OF THE STUDYThis study aimed to elucidate the therapeutic effect of QAFA on allergen-induced CVA, providing deep insights into the underlying mechanisms.MATERIALS AND METHODSUltra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) was employed to characterize the compositions, while UPLC was used to quantify the contents of its major components in QAFA. CVA model was established via sensitization and atomization with ovalbumin (OVA), and received 600 and 1200 mg/kg of QAFA via intragastric gavage. Cough response was assessed by stimulation with capsaicin (CAP). Then, airway hyperresponsiveness (AHR), ELISA, western blotting, RT-qPCR, and histological analyses, were applied to assess pulmonary function, pathological changes, and investigate mechanisms in CVA mice following QAFA treatment through the TRPV1/Ca²⁺-dependent NFAT-induced expression of TSLP and ferroptosis. Additionally, the effects and mechanisms of QAFA were validated using IL-4, CAP for stimulation, capsazepine (CPZ) for inhibition, and TRPV1 siRNA transfection in cells.RESULTSChemical analysis revealed that QAFA primarily contained sixteen compounds, with four main components including narirutin, naringin, hesperidin, and neohesperidin. In vivo, QAFA treatment alleviated cough and AHR, while concurrently reducing airway inflammation and mucus secretion in CVA mice. These effects were achieved by suppressing the TRPV1/NFAT/TSLP pathway and modulating the expression of ferroptosis-related proteins. In vitro, siTRPV1-transfected BEAS-2B cells demonstrated the involvement of the TRPV1 channel in IL-4-mediated Ca²⁺ influxes, ferroptosis, and regulation of TSLP production. QAFA and CPZ suppressed IL-4-induced TSLP production via the TRPV1/NFAT pathway and regulated the levels of ferroptosis-related proteins, while CAP counteracted the effect of QAFA on TSLP production in BEAS-2B cells. Furthermore, QAFA reduced IL-4 or CAP induced Ca²⁺ influx and IL-4 induced ferroptosis through TRPV1 mediation.CONCLUSIONSThis study demonstrated that QAFA improved pulmonary function and alleviated asthmatic inflammatory response in treating CVA probably through suppressing the TRPV1/Ca²⁺/NFAT/TSLP pathway and ferroptosis via TRPV1 mediation.

01 Feb 2025·Food Chemistry

Multiplex immunochromatographic test strip based on multicolor gold nanoparticles for the simultaneous detection of neomycin, penicillin, and chloramphenicol in food samples

Article

Author: Arsawiset, Supattra ; Teepoo, Siriwan ; Cheubong, Chehasan

In this study, we demonstrated an approach for the development of multiplex immunochromatographic test strip (MICS) for neomycin (NEO), penicillin (PEN), and chloramphenicol (CAP) detection using three different-colored gold nanoparticles. The gold nanoparticles: gold nanospheres (red), gold nanostars (blue), and gold nanoflowers (black) were applied as labels for MICS fabrication. The proposed MICS achieved a clearly visible limit of detection with cut-off values of 500, 5, and 0.5 μg L^-1 for NEO, PEN, and CAP, respectively within only 10 min. Such smartphone-based detection provided a limit of detection of 3.70 μg L^-1 for NEO, 0.10 μg L^-1 for PEN, and 0.008 μg L^-1 for CAP. The analysis of real samples by the developed MICS was well correlated with the enzyme-linked immunosorbent assay and liquid chromatography-mass spectrometry. The proposed MICS has the potential to be used for the simultaneous detection of NEO, PEN, and CAP with rapid, precise, and sensitive results.

01 Jan 2025·Bioresource Technology

Biotransformation of chloramphenicol by enriched bacterial consortia and the newly isolated bacterial strain Bordetella sp. C3: Detoxifying biotransformation pathway and its potential application in agriculture

Article

Author: Lu, Xingjun ; Zhao, Li ; Tan, Zewen ; Ren, Youhua ; Sun, Weimin ; Usman Ghani, Muhammad ; Luo, Yujiang ; Wang, Yuanliang

Limited sources of consortia/pure cultures that degrade chloramphenicol (CAP) and the incomplete biodegradation profiles of CAP hinder the remediation of CAP pollution. In this study, two CAP-degrading consortia (designated as CM and PM) were obtained after long-term acclimation, and Alcaligenaceae and Enterobacteriaceae enriched in CM and PM, respectively. Notably, Bordetella sp. C3, a new isolate belonging to the family Alcaligenaceae, was isolated from CM and capable of degrading 85.7 % 10 mg/L CAP at 30 ℃ and pH 7 in 10 d. The biotransformation of CAP by Bordetella sp. C3 was proposed as a detoxification process, including a novel initial degradation pathway: dechlorination of CAP into AP. Strain C3 can also function as a plant growth-promoting bacterium that solubilizes inorganic phosphate and produces siderophores and indole-3-acetic acid (IAA). This study expands our knowledge of the migration and transformation pathways of CAP and microbial community profiles during acclimatization.

100 Deals associated with CAP nanoparticles(BioSante Pharmaceuticals)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anthrax	Phase 1	-	Biosante Pharmaceuticals	-
Influenza, Human	Phase 1	-	Biosante Pharmaceuticals	-
Malaria	Discovery	-	Biosante Pharmaceuticals	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2012	Not Applicable	Colonic Cancer \| Metastatic Colorectal Carcinoma Adjuvant	409	Cap alone	(zoqsvjtpqw) = ipwwvqdumc fjbwumsoum (escxlzqdnm ) View more	-	20 May 2012
				Cap plus oxaliplatinCap plus oxaliplatin	(zoqsvjtpqw) = osaafwdxgh fjbwumsoum (escxlzqdnm )
AGITG MAX (ASCO2009)	Phase 3	Metastatic Colorectal Carcinoma First line	471	Cap	(owvzdnalbt) = ongodpnnme rgduudlrgq (uoffbhhcvv )	-	20 May 2009
				Cap Bev	(owvzdnalbt) = cmrwrvpico rgduudlrgq (uoffbhhcvv )
ASCO2009	Not Applicable	Gastrointestinal Neoplasms	44	PHY906	(knnevpkbbr) = uvbankrkzp onyskbdmsu (uxxfrvltav )	-	20 May 2009
				CAP alone	(knnevpkbbr) = gryxhpgubo onyskbdmsu (uxxfrvltav )
DCCG-CAIRO2 (ASCO2008)	Not Applicable	Colorectal Cancer	400	Arm A (Ox, Cap, Bev)	gadjenmfqi(pluecaapvc): OR = 3.85 (95% CI, 1.02 - 14.29), P-Value = 0.037 View more	-	20 May 2008
				Arm B (Ox, Cap, Bev, Cet)Arm B (Ox, Cap, Bev, Cet)
FOCUS2 (ASCO2007)	Not Applicable	Metastatic Colorectal Carcinoma	460	OxFU	(hzkehtpiym): HR = 0.87 (95% CI, 0.71 - 1.06), P-Value = 0.16	-	20 Jun 2007
				Cap